Our pipeline
Shaping the future of medicine
Our pipeline is grounded in robust scientific research and focused on developing well-tolerated therapies for rare cardiovascular and pulmonary diseases with high unmet medical need.
Cereno Scientific’s vision is to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.
Rare diseases with high unmet needs
A science-driven approach targeting underlying disease biology
Cereno Scientific is advancing a differentiated pipeline focused on rare cardiovascular and pulmonary diseases where current treatment options remain limited. Our pipeline includes two clinical-stage HDAC inhibitor programs, acting through epigenetic modulation, and one preclinical program targeting rare thrombotic disorders.
Together, these programs reflect a long-term scientific approach aimed at pioneering treatments through well-tolerated therapies that address key disease mechanisms.
Epigenetic modulation through HDAC inhibition
Cereno Scientific’s ambition is built around a novel disease-modifying approach targeting the underlying pathophysiology of a range of cardiopulmonary diseases.
CS1 in PAH
CS1 is a well-tolerated oral therapy with favorable safety profile and disease-modifying effects in development for the rare disease pulmonary arterial hypertension (PAH). A Phase IIa trial has successfully been completed and preparations for a Phase IIb is ongoing.
CS014 in PH-ILD
CS014 is targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD) as a differentiated oral therapy. It’s a once-daily HDAC inhibitor with favorable safety and tolerability. Preparations for a Phase II trial is ongoing.
CS585 in rare thrombotic disorders
CS585 represents a novel approach to the treatment of thrombosis without increased bleeding risk, which is a key limitation of current therapies. Preclinical development is ongoing.
Changing the lives of patients
Patients
At Cereno Scientific, patients are at the center of everything we do. We are committed to developing well-tolerated oral treatments for people living with rare and serious cardiovascular and pulmonary diseases, where current options are often limited.
By building on strong science and a deep understanding of disease biology, we aim to improve quality of life and address areas of significant unmet medical need.
News
View allPress release
09 Oct 2026
Cereno Scientific’s Nomination Committee Proposes Johan Eriksson for Election to the Board of Directors – Experienced Business Leader with Strong Shareholder Commitment
Press release
09 Oct 2026
Cereno Scientific gives notice to attend Extraordinary General Meeting
Press release
08 Oct 2026
Cereno Scientific expects up to 15 sites to be activated by year-end 2026 in the global Phase IIb EPIMODE trial; maintains Q4 2028 timeline for topline results
For Investors
Go to InvestorsCRNO.B
The SharePresentations
View all
Invest in Cereno
Deeper insights
Stories
Insights and explainers to support understanding of the field, our activities and why innovation in medicine matters.
Story
Living with PAH
In this interview Hall Skåra shares his experience of living with PAH.
Story
Understanding the Additional 12-Month EAP Analyses for CS1 – What This Means for Investors
The findings provide further long-term clinical experience with CS1 and add important context as the company prepares to initiate its global Phase IIb study, where CS1’s potential disease-modifying profile in PAH will be further evaluated in a controlled setting.
Story
Professor Marc Humbert: The Future of PAH Treatment Lies in Disease Modification
Pulmonary arterial hypertension (PAH) remains a serious and life-threatening disease despite significant advances in treatment over the past decades. As the field increasingly shifts its focus from symptom management toward disease modification, new therapeutic approaches targeting the underlying mechanisms of disease are gaining attention. In this interview, Professor Marc Humbert, one of the world's leading PAH experts and Chair of the Clinical Steering Committee for Cereno Scientific's CS1 program, shares his perspective on the current treatment landscape, key considerations in clinical development, and what may define the next generation of therapies for PAH.
Story
How to interpret the strategic value of the 12-month EAP data for CS1 – clarity on what this means for investors
Cereno Scientific recently confirmed that CS1 met its primary endpoint of safety and tolerability in the 12-month Expanded Access Program (EAP) with CS1 in pulmonary arterial hypertension (PAH), confirming that CS1 was well tolerated with a favorable safety profile . While based on a limited number of patients, the EAP represents an important step forward by adding longer-term clinical data to the CS1 program. The initial analysis of the EAP has been focused on the primary endpoint of safety and tolerability. Further analyses will be conducted on data from the EAP and Fluidda imaging sub-study evaluating changes in the pulmonary vessels during Q2 2026.
Story
What the initial insights from the EAP mean for the continued development of CS1 – an explanation for investors
Cereno Scientific has presented initial insights from an Expanded Access Program (EAP), in which patients with pulmonary arterial hypertension (PAH) were treated with the drug candidate CS1 for 12 months. The results confirm a favorable safety and tolerability profile during long-term treatment and are consistent with previously reported findings from the Phase IIa study.